O-GlcNAcylation as a Therapeutic Target for Alzheimer’s Disease

• Published in: Neuromolecular medicine Vol. 22; no. 2; pp. 171 - 193
• Main Authors: Park, Jinsu, Lai, Mitchell K. P., Arumugam, Thiruma V., Jo, Dong-Gyu
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2020; Springer Nature B.V
• Subjects: Alzheimer's disease; Amyloid precursor protein; Animal models; Biomedical and Life Sciences; Biomedicine; Dementia disorders; Geriatrics; Internal Medicine; N-Acetylglucosamine; Neurodegenerative diseases; Neurology; Neurosciences; O-GlcNAcylation; Post-translation; Proteins; Review; Tau protein; Therapeutic applications; Glucose metabolism; O-GlcNAcylation; Alzheimer’s disease; Neurodegeneration; O-GlcNAc
• ISSN: 1535-1084; 1559-1174
• DOI: 10.1007/s12017-019-08584-0

Alzheimer’s disease (AD) is the most common cause of dementia and the number of elderly patients suffering from AD has been steadily increasing. Despite worldwide efforts to cope with this disease, little progress has been achieved with regard to identification of effective therapeutics. Thus, active research focusing on identification of new therapeutic targets of AD is ongoing. Among the new targets, post-translational modifications which modify the properties of mature proteins have gained attention. O-GlcNAcylation, a type of PTM that attaches O-linked β- N -acetylglucosamine (O-GlcNAc) to a protein, is being sought as a new target to treat AD pathologies. O-GlcNAcylation has been known to modify the two important components of AD pathological hallmarks, amyloid precursor protein, and tau protein. In addition, elevating O-GlcNAcylation levels in AD animal models has been shown to be effective in alleviating AD-associated pathology. Although studies investigating the precise mechanism of reversal of AD pathologies by targeting O-GlcNAcylation are not yet complete, it is clearly important to examine O-GlcNAcylation regulation as a target of AD therapeutics. This review highlights the mechanisms of O-GlcNAcylation and its role as a potential therapeutic target under physiological and pathological AD conditions.